Literature DB >> 12394766

Lactobacillus species is more cytotoxic to human bladder cancer cells than Mycobacterium Bovis (bacillus Calmette-Guerin).

Shih Wee Seow1, Juwita Norasmara Bte Rahmat, Ameer Ali Kanakkappillai Mohamed, Ratha Mahendran, Yuan Kun Lee, Boon Huat Bay.   

Abstract

PURPOSE: We determined if Lactobacillus species has growth inhibitory effects in human bladder cancer cell lines and how this effect compares with the known effects of Mycobacterium bovis, that is bacillus Calmette-Guerin (BCG).
MATERIALS AND METHODS: The growth of MGH and RT112 cells were determined by cell counts after 24, 48 and 72 hours of exposure to L. casei strain Shirota (Yakult, Singapore) or L. rhamnosus strain GG (National Collection of Industrial and Marine Bacteria, Ltd., Aberdeen, Scotland) (1 x 10 and 1 x 10 cfu) or BCG (1 x 10 cfu) in the presence and absence of streptomycin. Annexin-V was used to monitor the presence of pre-apoptotic cells.
RESULTS: L. rhamnosus GG inhibited MGH proliferation and it was cytotoxic to RT112 cells (p <0.05). L. casei Shirota was cytotoxic to the 2 cell lines (p <0.05). BCG had a similar cytotoxic effect in MGH cells as Lactobacillus species but was not as effective in RT112 cells. Streptomycin abrogated the cytotoxic effect of Lactobacillus species but not that of BCG. Cytotoxic activity was not found in Lactobacilli culture supernates but it was induced in the presence of mammalian cells. L. rhamnosus GG induced apoptosis in RT112 but not in MGH cells. No apoptotic cells were detected after treatment with L. casei Shirota.
CONCLUSIONS: Lactobacillus species induced cytotoxic effects in bladder cancer cells. Unlike BCG, it requires bacterial protein synthesis. Like BCG, L. casei Shirota induces cell death primarily via necrosis. The cytoxicity of these lactobacilli in bladder cancer cells raises the possibility of using this species of bacteria as intravesical agents for treating bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12394766     DOI: 10.1097/01.ju.0000034353.97729.69

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

Review 1.  New therapies for non-muscle-invasive bladder cancer.

Authors:  Edmund Chiong; Kesavan Esuvaranathan
Journal:  World J Urol       Date:  2009-09-18       Impact factor: 4.226

Review 2.  The microbiome of the urinary tract--a role beyond infection.

Authors:  Samantha A Whiteside; Hassan Razvi; Sumit Dave; Gregor Reid; Jeremy P Burton
Journal:  Nat Rev Urol       Date:  2015-01-20       Impact factor: 14.432

Review 3.  Questions and challenges associated with studying the microbiome of the urinary tract.

Authors:  Yige Bao; Kait F Al; Ryan M Chanyi; Samantha Whiteside; Malcom Dewar; Hassan Razvi; Gregor Reid; Jeremy P Burton
Journal:  Ann Transl Med       Date:  2017-01

Review 4.  Anticancer effects of the microbiome and its products.

Authors:  Laurence Zitvogel; Romain Daillère; María Paula Roberti; Bertrand Routy; Guido Kroemer
Journal:  Nat Rev Microbiol       Date:  2017-05-22       Impact factor: 60.633

5.  Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer.

Authors:  Patrick Vianna Garcia; Letícia Montanholi Apolinário; Petra Karla Böckelmann; Iseu da Silva Nunes; Nelson Duran; Wagner José Fávaro
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  An In Vivo Study of Lactobacillus rhamnosus (PTCC 1637) as a New Therapeutic Candidate in Esophageal Cancer.

Authors:  Malihe-Sadat Hashemi-Khah; Nazila Arbab-Soleimani; Mohammad-Mahdi Forghanifard; Omid Gholami; Saba Taheri; Sakineh Amoueian
Journal:  Biomed Res Int       Date:  2022-06-24       Impact factor: 3.246

7.  Expression of chemokine/cytokine genes and immune cell recruitment following the instillation of Mycobacterium bovis, bacillus Calmette-Guérin or Lactobacillus rhamnosus strain GG in the healthy murine bladder.

Authors:  Shih Wee Seow; Juwita N Rahmat; Boon Huat Bay; Yuan Kun Lee; Ratha Mahendran
Journal:  Immunology       Date:  2008-01-22       Impact factor: 7.397

Review 8.  Activation of B cells by a dendritic cell-targeted oral vaccine.

Authors:  Bikash Sahay; Jennifer L Owen; Tao Yang; Mojgan Zadeh; Yaima L Lightfoot; Jun-Wei Ge; Mansour Mohamadzadeh
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

9.  Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and Cancer.

Authors:  Wagner J Fávaro; Odilon S Nunes; Fabio Rf Seiva; Iseu S Nunes; Lisa K Woolhiser; Nelson Durán; Anne J Lenaerts
Journal:  Infect Agent Cancer       Date:  2012-06-18       Impact factor: 2.965

10.  BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking.

Authors:  Fanghong Chen; Guangjian Zhang; Yoshiki Iwamoto; William A See
Journal:  BMC Urol       Date:  2005-05-12       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.